Close Menu

New Products

Jan 27, 2020

Swift Biosciences, Opentrons Labworks: Automated 2S Turbo DNA Library Preparation

Swift Biosciences and Opentrons Labworks have launched pre-scripted, automated protocols for the Swift 2S Turbo DNA library preparation kit on the Opentrons OT-2 liquid handler.

The protocol can be combined with the Swift Deceleration Module to obtain longer fragments of 550 bp, control fragmentation time on automation platforms, or adjust sample elution buffer. 

Jan 27, 2020

Agilent SureSelect XT HS2 DNA Kit

Agilent Technologies has launched its SureSelect XT HS2 DNA kit, which it said will offer researchers a complete solution to choose workflow options. The firm said the kit allows users to multiplex hundreds of samples in one sequencing run, remove sample contamination by indexing from reads, and improve error correction to detect variants with low allele frequencies. 

Jan 23, 2020

Integrated DNA Technologies xGen Exome Research Panel v2

Integrated DNA Technologies has launched the xGen Exome Research Panel v2.

The next-generation sequencing panel offers improved on-target rates and uniformityincreased sample coverage, updated content, and enhanced performance. The retail price is $8 per sample, which IDT said is a reduction of more than 50 percent, compared to the previous version. Each of the panel's 415,115 probes are individually synthesized on IDT's newest platform, Gemini, and manufactured for one large synthesis lot to ensure reproducible results and avoid lot-to-lot revalidations. Potential applications for the assays include population studies, rare disease research, and oncology, IDT said.

Jan 23, 2020

Meridian Bioscience High Specificity Pfu HS Mix

Meridian Bioscience launched a High-Specificity Pfu Hs Mix to provide high-fidelity amplification and amplification for companion diagnostic and clinical testing. The solution cuts down on the possibility of uneven amplification of diverse types of sequences. Meridian said the mix has "market-leading" properties in terms of inhibitor resistance, multiplexing, and low GC bias and can be used in next-generation sequencing and PCR applications. 

Jan 21, 2020

OptraHealth GeneFax Pro

OptraHealth has introduced a version of GeneFax Pro on the Microsoft Azure Marketplace. GeneFax Pro is a conversational chatbot program featuring natural-language processing and artificial intelligence to educate patients about genetic testing, gauge interest in specific tests, and automate pre-test counseling and patient consent. 

Jan 17, 2020

MGI Tech: DNBSEQ-G400 FAST

MGI Tech has launched the DNBSEQ-G400 FAST next-generation sequencer in China and Japan. The G400 is also known as MGISEQ-2000 in China and some other markets.

The G400 FAST is a mid-throughput instrument offering maximum output of 330 gigabases for applications including targeted NGS, single-cell sequencing, and whole-genome and -exome sequencing.

The instrument offers two lanes with 550 million effective reads per flow cell. The average run time is between 12 and 37 hours.  Maximum read length is PE150.

Jan 17, 2020

MGI One Million Genomes Total Solution

MGI has released One Million Genomes Total Solution, a software and hardware solution for large-scale population genome sequencing projects that combines sample preparation, high-throughput sequencing, and data analysis. The package consists of a whole-blood pretreatment system that has an annual output of up to 600,000 samples, an automated library preparation system with an annual output of up to 500,000 samples, and MGI's ultra-high-throughput DNBSEQ-T7 sequencer that can sequence 600,000 to 800,000 samples per year. It also includes a data processing platform with computing and storage capabilities that can analyze 100,000 to 1 million samples per year. In addition, the solution integrates a laboratory management system. It uses blockchain technology for data security and privacy.

Jan 17, 2020

Oxford Nanopore Technologies R10.3 Nanopore Chemistry

Oxford Nanopore Technologies has released flow cells using the R10.3 nanopore chemistry. It is currently available for MinIon and PromethIon sequencers and will be available for Flongle flow cells at a later time. The R10.3 chemistry, which is suitable for use with the LSK109 kit at launch, improves on the R10. Like the R10, it uses a pore with a longer barrel and a dual reader head, which improves resolution of homopolymers and consensus accuracy. Compared to the R10, it has increased throughput and capture, is compatible with PromethIon flow cells, has input amounts closer to the R9.4.1 chemistry, and has improved raw accuracy to match the R9.4.1 and to support enhanced variant calling.

Jan 14, 2020

Congenica Neuro

Congenica has introduced Congenica Neuro, a module for the company's clinical decision support platform to help physicians characterize epilepsy and neurodevelopmental disorders. The technology automates prioritization of genetic variants and helps accelerate the identification, review, and reporting of de novo variants by comparing test results to curated gene panels and preconfigured filters, the company said. 

Jan 14, 2020

Biocept Target Selector for CSF

Biocept's Target Selector liquid biopsy assays are now available to physicians to evaluate patients' cerebrospinal fluid for the presence of circulating tumor cells and biomarkers for patients with breast or lung cancer suspected of brain or central nervous system metastases. The presences of such cells may indicate brain metastases. Biocept said that up to 30 percent of patients with breast cancer and up to 36 percent of patients with lung cancer will develop brain metastases.  

Jan 14, 2020

Oxford Gene Technology: SureSeq CLL + CNV Panel

Oxford Gene Technology has launched the SureSeq CLL + CNV Panel for cancer research. The next-generation sequencing assay has been designed in collaboration with cancer experts to detect 12 key genes and five chromosomal regions implicated in chronic lymphocytic leukemia (CLL) progression.

The panel alleviates the burden of running multiple assays and delivers a comprehensive genomic profile for each CLL sample using a single workflow. It can identify loss of heterozygosity, copy number variation with a size range of a single exon to the whole gene, loss of chromosomal arms, and whole chromosome gains in trisomy 12. It comes with complimentary data analysis software.

Jan 14, 2020

Genome Diagnostics NGSengine

Genome Diagnostics has released a new version of its NGSengine human leukocyte antigen typing software. The updated NGSengine is now capable of exporting HLA typing results of individual samples directly to the Predicted Indirectly Recognizable HLA Epitopes (PIRCHE) matching-services website, thanks to a recent partnership between Netherlands-based GenDx and German firm PIRCHE. This, the company said, will give laboratories the ability to predict indirectly recognizable HLA epitopes for either hematopoietic stem cells or solid organs.

Jan 13, 2020

Bio-Rad Laboratories: SEQuoia

Bio-Rad Laboratories announced the launch of the SEQuoia Complete Stranded RNA Library Prep Kit for RNA-Seq library preparation. The kit uses SEQzyme, an enzyme that couples cDNA synthesis with adapter addition in a continuous synthesis reaction. It is compatible with a broad range of sample inputs and allows capture of the complete transcriptome, including short and long RNAs, in a single library prep. The kit generates cDNA libraries suitable for strand-specific next-generation sequencing on Illumina sequencers in less than four hours. It also includes access to the integrated SeqSense analysis solution to process and quality control sequencing data for all RNA biotypes in the library within a single analysis pipeline.

Jan 13, 2020

OncoCyte DetermaRx

OncoCyte has launched the DetermaRx, test for identifying early-stage lung cancer patients who may benefit from adjuvant chemotherapy after surgical resection. The test was formerly known as the Razor treatment stratification test and was being developed by Razor Genomics, which OncoCyte acquired in September. Regulators in Canada have approved the test for marketing in that country, the Irvine, California-based firm said. In the US, Florida Precision Oncology and the Leonard Cancer Institute at Mission Hospital in Mission Viejo, California have signed up as early access users of the test, OncoCyte said. It said that in a clinical study, high-risk patients identified by the test post-surgery and treated with adjuvant chemotherapy had a "significant" increase in survival rates. 

Jan 13, 2020

Dovetail Genomics: Genome Assembly Services With Omni-C

Dovetail Genomics has launched an expanded menu of genome assembly services, including 3D genome conformation analysis, annotations, and chromosome-scale assemblies.

The services leverage the firm's Omni-C technology, which provides improved scaffolding, SNP detection, and haplotype phasing.

Jan 09, 2020

Qiagen QiaSymphony PowerFecal Pro DNA Kit

Qiagen has launched the QiaSymphony PowerFecal Pro DNA Kit for the isolation of microbial genomic DNA from stool and soil using the QiaSymphony automation platform. The new kit enables automated, time-saving, standardized extraction of inhibitor-free DNA from stool and soil samples for metagenomic analysis, and is designed for 192 samples with continuous loading of 24-sample batches. Qiagen said that its new PowerBead Pro tubes are included in the kit for homogenization. The beads and optimized chemistry enable more efficient lysis of bacteria and fungi.

Jan 09, 2020

Pillar Biosciences Onco/Reveal Solid Tumor Panel

Pillar Biosciences has launched the Pillar Onco/Reveal Solid Tumor Panel, a 47-gene enrichment assay for research use. The panel leverages Pillar's SLIMamp enrichment chemistry, which uses primers that are designed to form stem loops to suppress unwanted amplicons during PCR amplification, enabling multiplexed NGS library preparation in a single tube. The test was licensed from Columbia University and recently received approval from the New York State Department of Health.

Jan 09, 2020

Personalis NeXT Dx Test

Personalis has launchedthe NeXT Dx Test, a next-generation sequencing panel designed to help oncologists identify potential therapies and clinical trial options for cancer patients. The assay analyzes approximately 20,000 genes in both the tumor exome and transcriptome, and includes advanced analytics to provide a diagnostic report on genetic alterations in medically important cancer genes, as well as emerging immunotherapy-related biomarkers such as microsatellite instability status and tumor mutational burden.

Jan 08, 2020

Viracor Eurofins 'Viracor TRAC'

Viracor Eurofins has begun offering its Viracor TRAC donor-derived, cell-free DNA assay for diagnosing kidney transplant rejection. The noninvasive liquid biopsy test has similar characteristics to other donor-derived cfDNA assays on the market, Viracor Eurofins said. Two ongoing prospective and one retrospective clinical trials are underway to further develop clinical data to support use of the test. The current gold standard for diagnosing kidney transplant rejection and surveillance is organ biopsy, which is both expensive and can lead to multiple complications for the patient, the firm noted. 

Jan 07, 2020

PreventionGenetics Rapid PGxome WES Test

PreventionGenetics has added the Rapid PGxome whole-exome sequencing test to its clinical testing menu. It is ideal for situations where a rapid genetic diagnosis is essential, including patients with neonatal, infantile,  or early childhood onset severe disorders, the company noted. Rapid PGxome starts at $2,290 per test and must be ordered by a qualified healthcare provider. It has a turnaround time of 14 days and, in cases with a clear positive result, a preliminary report may be issued in as few as six days.

Jan 06, 2020

Sysmex Ipsogen JAK2 DX

Sysmex has launched the ipsogen JAK2 DX reagent after the product received health insurance coverage in Japan on Jan. 1. The Kobe, Japan-based firm said that it received marketing approval for the gene testing kit that measures the JAK2V617F mutation quantitatively in December 2018. The test is used to diagnose certain hematopoietic tumors, specifically polycythemia vera, essential thrombocythemia, and primary myelofibrosis. Sysmex inked a distribution deal with Ipsogen (now part of Qiagen) in 2011 covering Japan that allows Sysmex to distribute some Ipsogen blood cancer products in that country.

Jan 02, 2020

AMS Biotechnology cfPure Max Cell-Free DNA Purification Kit

AMS Biotechnology has released the cfPure Max kit for circulating cell-free DNA purification. It is designed for samples with a volume of at least 5 ml. The company's cfPure kits use silica-coated paramagnetic particles to purify cell-free DNA from less than 1 ml to more than 10 ml of serum or plasma, for downstream applications such as bisulfite sequencing, next-generation sequencing, or qPCR.

Dec 19, 2019

Lucid Diagnostics EsoGuard Esophageal DNA Test

PAVmed's Lucid Diagnostics subsidiary has launched its EsoGuard Esophageal DNA Test as a laboratory-developed test after completing CLIA/CAP certification of the test. EsoGuard is a DNA test designed to facilitate the diagnosis of Barrett's esophagus and related precursors to esophageal adenocarcinoma.

EsoGuard LDT is performed on cells which are noninvasively sampled from the distal esophageal lining and shipped in a custom preservative solution to the ResearchDx facility in Irvine, California, where the DNA is immediately extracted. The DNA is then subjected to bisulfite conversion, PCR amplification, and next-generation sequencing to determine the methylation status of 31 sites on the vimentin and cyclinA1 genes, the company said. A bioinformatic algorithm is used to calculate the percentage of DNA molecules in which a proportion of methylated sites on either gene exceeds a certain threshold, delivering a positive or negative result.

A positive result has been associated with the presence of non-dysplastic Barrett's esophagus, dysplastic Barrett's esophagus, or esophageal adenocarcinoma, PAVmed added.

Dec 16, 2019

SpeeDx: ResistancePlus MG FleXible

SpeeDx has launched the ResistancePlus MG FleXible for the GeneXpert System in Europe. The test detects Mycoplasma genitalium and markers associated with azithromycin resistance. It is now available in France and the UK, to be followed by the rest of the EU, Australia, and New Zealand. Cepheid is the exclusive distribution partner of the test through its FleXible Cartridge program for the GeneXpert System.

Dec 16, 2019

BioIVT NGS Services

BioIVT has launched next-generation sequencing services. The services include target mutation and subject cohort identification, human tissue procurement, sample and library preparation, sequencing, bioinformatics, and project design and management. The firm is offering both standard and custom services for assay validation as well as exploratory research.

Pages

A Harvard University professor has been charged with making false claims regarding funds he received from China, the New York Times reports.

Discover magazine reports that animal dissections might dissuade students from science careers, but that a firm has developed synthetic frogs for dissections.

Nature News reports that a US panel is reviewing current guidelines for federally funded gain-of-function viral research.

In PNAS this week: de novo mutation patterns among the Amish, an alternative RNA-seq method, and more.